Cell No. : Cell Name
RCB1702 : SLVL
update : 2024/01/17
|
Comment | Human cell line derived from splenic B cell lymphoma. |
Comment from the depositor | |
Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
Remarks | |
Order Form |
Order Form(C-0005.pdf)
 
MTA(C-0007.pdf)
 
MTA(C-0007p.pdf)
 
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
Basic information
|
Depositor |
Inokuchi, Koiti
|
Originator |
Inokuchi, Koiti
|
Year of deposit |
2000
|
Another name |
VL51
|
Animal |
_human
< Mammals
|
Genus |
Homo
|
Species |
sapiens
|
Race |
Japanese
|
Gender |
Female
|
Age at sampling |
70 years
|
Tissue |
spleen
|
Disease name |
spleuic lymphoma
|
Classification |
cancer
|
|
Lifespan |
infinite
|
Morphology |
lymphocyte-like
|
Cellosaurus(Expasy) |
CVCL_3169
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
Culture method |
|
浮遊細胞の培養に関する一般的な注意(Japanese)
|
Culture medium |
|
RPMI1640 + 10% FBS
|
Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 4 split
|
SC frequency |
|
Subculture : 1-2 times/week, Medium Renewal : 2 times/week
|
Temperature |
|
37
℃
|
CO2 concentration |
|
5
%
|
Freeze medium |
|
Medium + 10% DMSO
|
Freezing method |
|
Slow freezing
|
Mycoplasma |
|
(-)
|
Animal PCR |
|
OK
|
Virus (HIV) |
|
LT 400
|
Virus (HTLV-1) |
|
(-)
|
Isozyme |
|
LD, NP
|
Chromosome mode |
|
75-82(50) : /77(3),78(10),79(7),80(11),81(11),82(6)
|
STR(human) |
|
OK
|
Reference information |
Reference |
1
|
User's Publication |
6
|
User's Publication |
16945
Yano H, Fujiwara Y, Horlad H, Pan C, Kai K, Niino D, Ohsawa K, Higashi M, Nosaka K, Okuno Y, Tamaru JI, Mukasa A, Matsuoka M, Komohara Y.
Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapy
Cancer Sci
2022
113(6):2129-2143
PubMed ID: 35343027
DOI: 10.1111/cas.15349
|
11433
Chiu H, Trisal P, Bjorklund C, Carrancio S, Toraño EG, Guarinos C, Papazoglou D, Hagner PR, Beldi-Ferchiou A, Tarte K, Delfau-Larue MH, Morschhauser F, Ramsay AG, Gandhi AK.
Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
Br. J. Haematol.
2019
PubMed ID: 30767211
DOI: 10.1111/bjh.15797
|
10269
Komohara Y, Ma C, Yano H, Pan C, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Okuno Y, Nosaka K, Shimosaki S, Morishita K, Matsuoka M, Wakayama T, Takeya M.
Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophages
J Clin Exp Hematop
2017
57:15-20
PubMed ID: 28420814
DOI: 10.3960/jslrt.17003
|
13994
Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y.
An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma
Cancer Sci
2016
107(11):1696-1704
PubMed ID: 27564404
DOI: 10.1111/cas.13065
|
15339
Bai B, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Takeya M, Komohara Y.
Role of Stat3 activation in cell-cell interaction between B-cell lymphoma and macrophages: the in vitro study
J Clin Exp Hematop
2013
53(2):127-33
PubMed ID: 23995109
DOI: 10.3960/jslrt.53.127
|
18937
Komohara Y, Horlad H, Ohnishi K, Ohta K, Makino K, Hondo H, Yamanaka R, Kajiwara K, Saito T, Kuratsu J, Takeya M.
M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma
J Clin Exp Hematop
2011
51(2):93-9
PubMed ID: 22104307
DOI: 10.3960/jslrt.51.93
|